WASHINGTON, Dec 4 (Reuters) - U.S. regulators complained that an AstraZeneca PLC (AZN.L: Quote, Profile, Research, Stock Buzz) sales representative suggested an unapproved use of the company’s schizophrenia drug Seroquel to a physician, according to a letter released on Thursday.
